Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 929 of 6351
-
CBD as a calming agent for Scan-Related anxiety in advanced breast cancer?
Symptom relief OngoingThis research study is investigating use of a single dose of cannabidiol (CBD) to help manage anticipatory anxiety in participants with advanced breast cancer poised to undergo computed tomography (CT) or positron emission tomography (PET) to assess tumor burden. The name of the…
Phase 2 • Sponsor: Dana-Farber Cancer Institute • Aim: Symptom relief
Last updated Aug 21, 2026 00:00 UTC
-
New drug guselkumab aims to tame Crohn's Flare-Ups
Disease control OngoingThe purpose of this study is to evaluate the efficacy and safety of guselkumab in participants with Crohn's disease.
Phase 3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New combo targets tough lung cancer in early trial
Disease control OngoingThis phase Ib trial is to find out the best dose, possible benefits and/or side effects of osimertinib and tegavivint as first-line therapy in treating patients with EGFR-mutant non-small cell lung cancer that has spread to other places in the body (metastatic). Osimertinib and t…
Phase 1 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can augmented reality make spinal screws safer?
Disease control OngoingThe spinal navigation trial (SPINAV) is a randomized controlled trial (RCT) evaluating the use of computer-assisted navigation in surgery for spinal deformity
Sponsor: Karolinska Institutet • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
New combo therapy aims to stall lung cancer progression
Disease control OngoingIn this study, patients with metastatic non-small cell lung cancer that is EGFR-mutated, who have received at least 8 and not more than 12 weeks of treatment with osimertinib without demonstrating disease progression, will receive APL-101 in combination with osimertinib until pro…
Phase 1/2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Immunotherapy plus chemo shows promise for rare lung cancer
Disease control OngoingThis phase II clinical trial evaluates the efficacy, safety and tolerability of Atezolizumab in addition to standard of care chemotherapy (Platinum/Etoposide) in LCNEC.
Phase 2 • Sponsor: Technische Universität Dresden • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Trikafta passes long-term safety test in kids with cystic fibrosis
Disease control CompletedThe purpose of this study is to evaluate the long term safety, tolerability, efficacy and pharmacodynamics of elexacaftor (ELX)/tezacaftor (TEZ)/ivacaftor (IVA) in CF participants 2 years of age and older.
Phase 3 • Sponsor: Vertex Pharmaceuticals Incorporated • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New hope for liver cancer with vein invasion: triple therapy tested in phase 3 trial
Disease control OngoingCompare the efficacy and safety of camrelizumab, apatinib plus FOLFOX-HAIC and camrelizumab plus apatinib in hepatocellular carcinoma with portal vein invasion.
Phase 3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Could a simple protein infusion save more lives from septic shock?
Disease control Recruiting nowThe current guideline emphasizes fluid resuscitation as the mainstay of initial management for septic shock. Albumin has the oncotic activity to maintain intravascular volumes with additional beneficial properties in sepsis. Prior studies showed that the replacement of albumin mi…
Phase 4 • Sponsor: Asan Medical Center • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New 3-Drug cocktail targets Hard-to-Treat brain tumors
Disease control Recruiting nowThis study will test the safety and effectiveness of a combination of pembrolizumab, olaparib, and temozolomide to see how well these drugs work when given together in people with a glioma that either did not respond to previous treatment or came back after treatment.
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New Antibody-Drug combo aims to tackle tough lymphoma
Disease control Recruiting nowThe purpose of this Phase 2/3, randomized, multisite, open-label, dose confirmation, and expansion study is to evaluate the safety, and efficacy of zilovertamab vedotin (ZV) in combination with standard of care options for the treatment of rrDLBCL. This study will be divided into…
Phase 2/3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Blood filter may boost stroke recovery
Disease control PausedDelipid Extracorporeal Lipoprotein filter from Plasma (DELP) has been found to improve neurological function and life ability of AIS patients and approved for the treatment of AIS by China Food and Drug Administration (CFDA). A recent study imply that the neuroprotective effect o…
Sponsor: General Hospital of Shenyang Military Region • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Could stem cells help kids with New-Onset diabetes?
Disease control OngoingThis is a combined phase 1 and 2 study in 66 subjects, male or female, between 7-21 years of age that have recently (\< 6 months) been diagnosed with type 1 diabetes. The first phase 1 part of the study includes six subjects openly receiving allogeneic Wharton's jelly derived mes…
Phase 1/2 • Sponsor: Uppsala University Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New study tests if proton radiation can spare brain tissue without hurting survival
Disease control Recruiting nowProton therapy is a powerful tool enabling oncologists to spare normal tissue around the target for irradiation much better than what can be achieved with photon irradiation. The infiltrative nature of IDH-mutated grade II and III diffuse glioma, however, renders proton therapy a…
Sponsor: Oslo University Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Donor CAR-T cells take on aggressive t-cell leukemia in early trial
Disease control CompletedThe purpose of this study is to evaluate the safety, recommended dose, and preliminary anti-tumor activity of WU-CART-007 in patients with relapsed or refractory (R/R) T-cell acute lymphoblastic leukemia (T-ALL) or lymphoblastic lymphoma (LBL).
Phase 1 • Sponsor: Wugen, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Blood test aims to catch lung cancer before it spreads
Diagnosis OngoingThe SHIELD (Screening for High Frequency Malignant Disease) study is a prospective, observational, multi-site basket design trial without randomization. The primary objective of the study is to evaluate the sensitivity and specificity of a blood-based GuardantLUNAR-2 test to dete…
Sponsor: Guardant Health, Inc. • Aim: Diagnosis
Last updated Jul 08, 2026 00:00 UTC
-
New MS pill aims to slash relapses in major trial
Disease control OngoingMulti-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adults with Relapsing Multiple Sclerosis (ENSURE-2)
Phase 3 • Sponsor: Immunic AG • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Wearable defibrillator jewel P-WCD tested in 322 High-Risk patients
Disease control CompletedThe Jewel IDE Study: A Clinical Evaluation of the Jewel P-WCD in Subjects at High Risk for Sudden Cardiac Arrest. ("JEWEL")
Sponsor: Element Science, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New combo therapy aims to shrink head and neck tumors before surgery
Disease control OngoingThe purpose of this study is to evaluate the efficacy of neoadjuvant immunoradiotherapy (NIRT) prior to surgery for the treatment of stage III and IVA HPV- HNSCC.
Phase 2 • Sponsor: Providence Health & Services • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New hope for aggressive breast cancer: drug combo aims to wipe out tumors before surgery
Disease control OngoingThis study aims to investigate efficacy and safety of neoadjuvant toripalimab plus docetaxel and carboplatin in patients with localized triple-negative breast cancer.
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC